The US Food and Drug Administration (FDA) has approved Zepbound, a medication, for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity. This is the first drug treatment option for certain patients with OSA.
Zepbound works by reducing appetite and food intake through hormone activation, resulting in weight loss, which also improves OSA symptoms. The approval is based on two studies involving 469 adults without type 2 diabetes. Participants who received Zepbound experienced a significant reduction in apnea events compared to those taking a placebo. A higher proportion of participants treated with Zepbound achieved remission or mild OSA.
However, Zepbound may cause side effects such as nausea and vomiting, diarrhea, and abdominal discomfort. Patients with a history of thyroid cancer or multiple endocrine neoplasia syndrome type 2 should not use the medication. Additionally, patients with kidney disease, diabetes, and depression should be monitored closely while taking Zepbound.
Zepbound’s approval is a significant step forward for patients with OSA. It has received Fast Track, Priority Review, and Breakthrough Therapy designations from the FDA.
Source: https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea